Results 11 to 20 of about 5,116,830 (334)

International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors [PDF]

The journal of liquid biopsy
Circulating tumor DNA (ctDNA) testing has transformed precision oncology by enabling the non-invasive detection of actionable mutations. To facilitate broader clinical adoption and improve testing accuracy, standardized quality criteria must be clearly ...
Nicola Fusco, K. Venetis, F. Pepe, O. Shetty, S. C. Fariñas, Simon Heeke, J. Burnier, Simon J. Patton, Ellen Heitzer, G. Nigita, Paul Hofman, Maria-Jose Serrano, M. Cristofanilli, E. Jantus-Lewintre, David Gandara, C. Rolfo, U. Malapelle   +16 more
semanticscholar   +3 more sources

Liquid Biopsy: Current advancements in clinical practice for bladder cancer [PDF]

The journal of liquid biopsy
Bladder cancer is the ninth most common malignancy worldwide, with two clinically distinct forms: non-muscle-invasive disease, characterized by high recurrence and excellent long-term survival, and muscle-invasive disease, associated with poorer outcomes.
F. Crocetto, U. Amicuzi, M. Musone, M. Magliocchetti, D. Di Lieto, Simone Tammaro, A. Pastore, A. Fuschi, Roberto Falabella, Matteo Ferro, Roberto Bianchi, M. Finati, G. Busetto, G. Lucarelli, F. D. Del Giudice, V. F. Caputo, Raffaele Balsamo, D. Terracciano   +17 more
semanticscholar   +3 more sources

Liquid Biopsy and NSCLC [PDF]

Lung Cancer Management, 2016
In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance.
Trombetta, D., Sparaneo, A., Fabrizio, F. P., Muscarella, L. A.   +3 more
openaire   +4 more sources

Harmonizing definitions in liquid biopsy: A terminology framework by the international society of liquid biopsy. [PDF]

J Liq Biopsy
The rapid expansion of liquid biopsy (LB) throughout the cancer care continuum is evidenced by the striking increase in annual publications, rising from approximately 100 per year in the early 2000s to more than 2200 in recent years.
Jantus-Lewintre E, Calabuig-Fariñas S, Gandara D, Raez L, Leighl NB, Fusco N, Khorshid O, Mayo de Las Casas C, Reduzzi C, Urum Y, Aggarwal C, Serrano MJ, Rolfo C, Malapelle U.   +13 more
europepmc   +2 more sources

Attitudes of cancer patients toward ctDNA-based liquid biopsy for follow-up. [PDF]

Mol Oncol
This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Chhajlani S, Mariën L, De Weerdt C, Wouters S, Teuwen LA, Prenen H, Janssens K, Vandamme T.   +7 more
europepmc   +2 more sources

Liquid Biopsy and Colorectal Cancer

South Asian Journal of Cancer
Abstract The majority of patients with colorectal cancer (CRC) will ultimately develop metastasis. Identifying specific molecular characteristics in them can help optimize their management in a personalized manner. This requires a noninvasive method for frequent sampling.
Shyam Aggarwal, Anuradha Chougle, Vineet Talwar, Pragya Shukla, Nitesh Rohtagi, Amit Verma, Rajesh Pasricha, Bhawna Sirohi, Chaturbhuj Agarwal, Sunil Pasricha, R. K. Choudhary, Gautam Goyal   +11 more
openaire   +4 more sources

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer

Frontiers in Oncology, 2023
BackgroundThe term “neo-RAS wild-type” refers to the switch to RAS wild-type disease in plasma circulating tumor DNA (ctDNA) from originally RAS mutant colorectal cancers.
Chiara Nicolazzo, Valentina Magri, Luca Marino, Francesca Belardinilli, Federica Di Nicolantonio, Gianluigi De Renzi, Salvatore Caponnetto, Michela De Meo, Giuseppe Giannini, Daniele Santini, Enrico Cortesi, Paola Gazzaniga   +11 more
doaj   +1 more source

Liquid biopsy from research to clinical practice : focus on non-small cell lung cancer

, 2021
: Introduction In the current era of personalized medicine, liquid biopsy has acquired a relevant importance in patient management of advanced stage non-small cell lung cancer (NSCLC).
Pisapia, Pasquale, De Miguel-Perez, Diego, Nuzzo, Pier Vitale, Addeo, Alfredo, Jantus-Lewintre, Eloisa, Rolfo, Christian, Bellosillo, Beatriz, Serrano, Maria Jose, Malapelle, Umberto, Arrieta, Oscar, Cardona, Andres F., Denninghoff, Valeria, Pauwels, Patrick, Troncone, Giancarlo, Raez, Luis E., Gandara, David R., Duran, Ignacio, Pickering, Edward M., Russo, Alessandro, Cristofanilli, Massimo, O'Byrne, Ken   +20 more
core   +2 more sources

AIFM2 promotes hepatocellular carcinoma metastasis by enhancing mitochondrial biogenesis through activation of SIRT1/PGC-1α signaling

Oncogenesis, 2023
AIFM2 is a crucial NADH oxidase involved in the regulation of cytosolic NAD+. However, the role of AIFM2 in the progression of human cancers remains largely unexplored.
Sanxing Guo, Fengying Li, Yixuan Liang, Yufei Zheng, Yingyi Mo, Deyao Zhao, Zhixiong Jiang, Mengmeng Cui, Lixia Qi, Jiaxing Chen, Lixin Wan, Guoyong Chen, Sidong Wei, Qi Yang, Junqi Liu   +14 more
doaj   +1 more source

Overview of liquid biopsy

, 2022
New studies are mainly focused on the new, minimally invasive biomarkers presenting in body fluids as the real-time representative of tumors, entitled “liquid biopsy.” Liquid biopsy contains tumor-derived cells, nucleic acids (DNA, RNA), and tumor ...
Yarandi V. A., Aghamir S. M. K., Khatami F., Rezaeian A., Fiorentino M.   +4 more
core   +1 more source